Loading data
MCRBNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 789 k USD | 0 USD | 0 USD | 7.13 m USD | 143.86 m USD |
| Research and development expense | 49.06 m USD | 64.6 m USD | 117.6 m USD | 109.65 m USD | 141.89 m USD |
| Operating profit | -93.97 m USD | -121.32 m USD | -195.1 m USD | -179.91 m USD | -64.49 m USD |
| Income tax expense | 0 USD | — | — | — | — |
| Net income (reported basis) | 5.7 m USD | 136 k USD | -113.72 m USD | -250.16 m USD | -65.58 m USD |
| Net income attributable to common shareholders | 5.7 m USD | 136 k USD | -113.72 m USD | -250.16 m USD | -65.58 m USD |
| Basic earnings per share | 0.64 USD/share | 0 USD/share | -17.77 USD/share | -2.31 USD/share | -0.72 USD/share |
| Diluted earnings per share | 0.64 USD/share | 0 USD/share | -17.77 USD/share | -2.31 USD/share | -0.72 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.